Abstract
Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence. In a post hoc analysis of a randomized trial (N = 304), app-based remote symptom monitoring improved 12-month AET adherence among premenopausal women (App-only: 53.9% vs. EUC: 25.0%), with no benefit for postmenopausal women. Findings suggest remote monitoring may help close adherence gaps in younger patients. Prospectively registered on ClinicalTrials.gov: NCT03592771.
Subject terms: Breast cancer, Signs and symptoms
Introduction
Despite the survival benefits of oral adjuvant endocrine therapy (AET) for women with hormone receptor-positive early-stage breast cancer, adherence rates remain low, particularly among younger, premenopausal women. Younger women have the highest risk for AET nonadherence1,2 and have higher risks of recurrence and breast cancer mortality 3, which may be partly driven by their lower AET adherence. Nonadherence among premenopausal women may stem from more pronounced side effects4. Tamoxifen, the standard first-line AET for most premenopausal women, frequently causes hot flashes, night sweats, and leukorrhea through its selective estrogen receptor modulation and partial estrogen agonist effects in non-breast tissues5. Among premenopausal women with high-risk early-stage breast cancer, tamoxifen is commonly combined with ovarian function suppression using luteinizing hormone-releasing hormone agonists, which is associated with even more abrupt and severe symptoms6. For postmenopausal women, who have already undergone natural estrogen decline, the additional suppression from aromatase inhibitors, the preferred AET in this group, is typically less abrupt. In addition, premenopausal women also report great quality of life disruptions from AET side effects7, interfering with family responsibilities, career advancement, and social interactions8. Many younger survivors have noted a lack of support systems designed to address their specific needs8. These findings underscore the need for enhanced symptom management strategies for premenopausal women prescribed AET.
Our THRIVE trial tested the effectiveness of an app-based remote monitoring intervention, with and without additional tailored text messages, on 1-year oral AET adherence, but found no significant differences between randomized groups7. We conducted post-hoc analyses to examine whether the effectiveness of the remote monitoring intervention varied by menopausal status, hypothesizing greater effectiveness for premenopausal women.
Participant Characteristics
Among 304 women randomized (104 EUC, 98 App-only, and 102 App Plus Feedback), 26% (n = 74) were premenopausal at AET initiation. No participants had documented medication-induced menopause. Premenopausal participants were younger (mean age 45.3 vs. 63.2 years, p < 0.001), more likely to self-identify as Black (44.6% vs. 30.0%, p = 0.05), be prescribed tamoxifen (60.8% vs. 11.1%, p < 0.001), and have received chemotherapy (40.3% vs. 25.9%, p = 0.02, Table 1).
Table 1.
Baseline characteristics by menopausal statusa
| Characteristics | Premenopausal (N = 74) | Postmenopausal (N = 230) | P value |
|---|---|---|---|
| Age, years | |||
| Mean (Standard Deviation) | 44.8 (6.3) | 63.0 (7.8) | <0.001 |
| Race, n (%) | 0.05 | ||
| Black | 33 (44.6) | 69 (30.0) | |
| White | 38 (51.4) | 154 (67.0) | |
| Otherb | 3 (4.1) | 7 (3.0) | |
| Education, n (%) | 0.38 | ||
| High school or less | 12 (16.2) | 48 (20.9) | |
| Some college or more | 62 (83.8) | 182 (79.1) | |
| Income: Federal Poverty Level (FPL), n (%) | 0.33 | ||
| <100% FPL | 10 (13.5) | 22 (9.6) | |
| ≥100% FPL | 63 (85.1) | 198 (86.1) | |
| Missing | 1 (1.4) | 10 (4.4) | |
| Lower health literacyc, n (%) | 14 (18.9) | 45 (19.6) | 0.90 |
| Married or living with a partner, n (%) | 46 (62.2) | 156 (67.8) | 0.37 |
| Locationd, n (%) | 0.75 | ||
| Non-metro | 17 (23.0) | 57 (24.8) | |
| Metro | 57 (77.0) | 173 (75.2) | |
| Initial AET prescription, n (%) | <0.001 | ||
| Tamoxifen | 46 (62.2) | 27 (11.7) | |
| Anastrozole | 26 (35.1) | 178 (77.4) | |
| Exemestane or Letrozole | 2 (2.7) | 25 (10.9) | |
| Cancer stage at diagnosis, n (%) | 0.87 | ||
| DCIS | 8 (10.8) | 26 (11.3) | |
| I | 54 (73.0) | 161 (70.0) | |
| II–III | 12 (16.2) | 43 (18.7) | |
| Prior chemotherapy, n (%) | 29 (40.3) | 56 (25.9) | 0.02 |
| Prior radiation, n (%) | 47 (63.5) | 141 (63.5) | 1.00 |
| Study Arm, n (%) | 0.74 | ||
| EUC | 28 (37.8) | 76 (33.0) | |
| App | 23 (31.1) | 75 (32.6) | |
| App Plus Feedback | 23 (31.1) | 79 (34.4) |
DCIS Ductal carcinoma in situ, EUC Enhanced Usual Care, AET Adjuvant Endocrine Therapy.
aMenopausal status was determined via chart abstraction. For the 39 participants with undocumented status, those aged <50 were categorized as premenopausal, and those aged ≥50 as postmenopausal.
bAmong participants in the ‘Other’ race category (N = 10), 5 self-identified as Asian, 1 American Indian, 1 Hispanic, and 3 as mixed race.
cA lower health literacy is classified as responding Never/Rarely/Sometimes/Often to ‘How confident are you filling out medical forms by yourself?’, whereas a higher health literacy is classified as responding Always.
dRural-Urban Commuting Area Codes (RUCA) used to categorize residential location as metro if RUCA was 1 and non-metropolitan if RUCA was 2 to 10.
AET adherence
Figure 1 shows the adjusted percentage of participants adherent to AET by study arm and menopausal status. Among premenopausal women, 25.0% in the EUC arm were adherent, compared to 53.9% in the App-only arm (adjusted risk difference [aRD]: 28.9 percentage points [ppt]; 95% CI: 1.5, 56.3) and 32.7% in the App Plus Feedback arm (aRD: 7.7 ppt; 95% CI: –21.8, 37.2).
Fig. 1. Adjusted percentage of participants AET adherent by study arm and menopausal status.
One-year adherence to AET was defined as taking ≥80% of prescribed doses, as recorded by the connected pillbox. Days hospitalized and prescriber-advised pauses were excluded from the denominator. Percentages and 95% confidence intervals were estimated using a linear probability model that included an interaction term between study arm and menopausal status, followed by the margins command. Missing outcome data due to loss to follow-up (n = 38) were addressed using multiple imputation with chained equations (25 iterations), based on five nearest neighbors drawn from study arm, age, race, education, health literacy, marital status, rurality, income, cancer stage, prior chemotherapy/radiotherapy, and AET type. Missing menopausal status (n = 39) was imputed using age 50 as the cutoff based on the mean menopausal age in the US. Abbreviations: AET Adjuvant Endocrine Therapy, EUC Enhanced Usual Care, ppt percentage points. *P < 0.05.
Among postmenopausal women, there were no statistically significant differences by study arm: 67.4% in the EUC arm were adherent, compared to 53.3% in App-only (aRD: –14.1 ppt; 95% CI: –30.2, 2.0), and 57.3% in App Plus Feedback (aRD: –10.1 ppt; 95% CI: –26.6, 6.4).
The interaction coefficient showed a statistically significant 43.1 ppt greater App-only intervention effect for premenopausal versus postmenopausal women (95% CI: 11.2, 74.9), and a smaller and not statistically significant 17.8 ppt greater effect for the App Plus Feedback intervention (95% CI: –15.4, 51.0). Findings were consistent in sensitivity analyses without imputation for missing outcomes or menopausal status (aRD: 31.0 ppt for App-only vs. EUC; 95% CI: 1.9, 60.1, Supplementary Table S1).
Among premenopausal women, an app-based remote symptom and adherence monitoring intervention significantly improved 1-year oral AET adherence, but not among postmenopausal women. Consistent with prior studies1,2, without additional support, AET adherence in EUC was significantly lower among premenopausal women. Given their distinct adherence challenges, including higher AET-related symptom burden2,9, and greater comfort with technology10, findings from this post-hoc analysis support app-based remote monitoring as a potential scalable and effective strategy to improve adherence among younger, premenopausal breast cancer survivors. Moreover, because Black women are disproportionately diagnosed at younger ages11 and have lower AET adherence due to experiencing more severe symptoms12, targeting younger premenopausal women for remote symptom and adherence monitoring could potentially also help mitigate racial disparities in oral AET adherence.
Interestingly, among premenopausal women, participants receiving additional tailored messages showed a smaller, non-significant improvement in adherence compared to those receiving app-based monitoring alone. Prior studies found frequent messages or poorly tailored messages can sometimes lead to disengagement or message fatigue13. Fewer than half of App Plus Feedback participants in our study reported that the feedback messages felt personalized to their needs14. Nonetheless, app usage was similar across intervention arms and age groups, with over 70% of participants using the app at least half of the weeks enrolled14. It is possible that the additional messages offered limited benefit, or potentially reduced engagement when the messages were not perceived as personalized. These findings underscore the importance of designing feedback that is not only timely and appropriately frequent but also perceived as personally meaningful.
Among postmenopausal women, the app-based intervention, with or without additional messages, had no significant effect on 1-year adherence. This may be due to their generally higher oral adherence levels2, leaving less room for improvement. Additionally, older women are less likely to adopt or engage with mobile health interventions15. While our prior analyses found similar levels of app use across age groups, older participants were less likely to report satisfaction with the remote monitoring app14. Notably, AET adherence and persistence have been associated with significant disease-free survival benefits for younger, premenopausal women, with little benefit among older women1. Given our findings that a remote monitoring intervention was significantly more effective among premenopausal women, targeted strategies to support populations at higher risk for nonadherence may be beneficial to enhance adherence and improve survival. Conversely, postmenopausal women generally have higher AET adherence rates and may not require or benefit from additional adherence support.
Despite the study’s rigorous randomized design, several limitations should be noted. As this post-hoc analysis was not pre-specified, its findings should be confirmed in future trials focused on younger, premenopausal women. Moreover, menopausal status was imputed using age 50 as a proxy for participants with missing documented menopausal status, which may misclassify some individuals. However, sensitivity analyses excluding those with missing menopause status or primary outcome data produced similar results to the imputed findings, supporting the robustness of our findings. Adherence to other oral medications or injectables (e.g., GnRH agonists) was not captured. As a result, our adherence estimates reflect oral AET only. Additionally, our results are limited to English-speaking participants with access to a connected smartphone, all receiving care at a single large comprehensive cancer center that routinely monitored patient-reported symptoms during clinic visits. Thus, the findings may not be generalizable to other healthcare settings or broader patient populations. Future studies should aim to recruit more diverse populations, including non-English speakers, individuals without smartphone access, and treated in community-based clinics, and should capture adherence to multiple medication types, including injectables, to improve external validity.
This post-hoc analysis of a randomized controlled trial showed that remote monitoring improved oral AET adherence among premenopausal younger women, with no effect among postmenopausal women. The app combined with additional support text messages showed similar, but smaller, non-statistically significant trends for premenopausal women. These exploratory findings highlight the potential of remote therapeutic monitoring of patient reported outcomes as a scalable strategy to support oral AET adherence among premenopausal individuals, who face unique adherence challenges, are more comfortable engaging with technology, and may derive larger survival benefits from improved adherence.
Methods
This non-blinded randomized controlled trial included women with early-stage breast cancer who were prescribed AET between November 2018 and June 2021 at a large comprehensive cancer center with 14 clinics. The enrollment survey asked about sociodemographic characteristics (race, ethnicity, educational level, household income, health literacy)16,17. Menopausal status and clinical characteristics were abstracted from participant’s medical charts at AET initiation. For the 39 participants with undocumented menopausal status, menopausal status was imputed using age 50 as the cutoff based on the mean menopausal age in the US11.
Consented participants were randomized into one of three conditions: (1) App-only, received 6 months of access to the adherence and symptom remote monitoring app, with weekly reminders, and reports of severe or increasing symptoms and missed doses triggering follow-ups from the oncology team; (2) App Plus Feedback, same as the App group plus weekly educational and motivational text messages for 6 months; or (3) Enhanced Usual Care (EUC) which included standard care with patient-reported symptom monitoring at each clinic visit. Consented patients who completed the enrollment survey were randomized via REDCap18 into one of three groups using race-stratified block randomization (White vs. other), with a block size of six. Stratification by race ensured balance across groups.
The THRIVE study protocol has been previously described and was approved by the University of Tennessee Health Science Center Institutional Review Board16,17. The study was prospectively registered on ClinicalTrials.gov (NCT03592771) on July 19, 2018.
Outcome
The primary study outcome was 1-year AET adherence, defined as taking ≥80% of prescribed doses captured by a connected pillbox (Wisepill RT300, Wisepill Technologies). If a participant changed AET regimens during the study period, adherence was assessed across the full year, incorporating both therapies. Days during prescriber-advised pauses or hospitalization were excluded from the denominator.
Statistical analysis
Primary analysis followed intent-to-treat principles where missing adherence data due to loss to follow-up were addressed using multiple imputations with chained equations19 based on five nearest neighbors drawn from study arm, age, race, education level, health literacy, marital status, rurality, income, cancer stage, prior chemotherapy/radiotherapy, and AET type conducted across 25 iterations.
A linear probability model estimated the interaction between study arm and menopausal status on 1-year adherence, using marginal effects to assess variation in intervention effectiveness by menopausal status. Sensitivity analyses were conducted without imputation for missing adherence data (n = 38) or participants without documented menopausal status (n = 39); the results are provided in Supplementary Table S1.
Supplementary information
CONSORT_2025_editable_checklist THRIVE post hoc meno
Acknowledgements
This study was funded by the National Cancer Institute (R01CA218155, PI: Graetz). The funding agency had no role in the design or conduct of the study. We thank the participants who volunteered their time to participate in this study. Preliminary results from this post hoc analysis were presented at the 2025 Society for Behavioral Medicine Annual Meeting and Scientific Sessions.
Author contributions
I.G. led the data analysis and wrote the main manuscript text. X.H., R.A.K., J.N.A., and T.M.W. contributed to the interpretation of findings and manuscript revisions. L.S.S. and G.V. provided clinical expertise and supported trial implementation. L.S.S., R.A.K., J.N.A., E.S., G.V., and T.M.W. contributed to study design. All authors reviewed and approved the final manuscript and agree to be accountable for all aspects of the work.
Data availability
De-identified data used in this study are available from the corresponding author upon reasonable request.
Code availability
The code used for these analyses is available from the corresponding author upon reasonable request.
Competing interests
I.G. received research grants from the Donaghue Foundation, NIH, Pfizer and PRIME Education, LLC outside the submitted work. X.H. received research support from the NIH, Donaghue Foundation, PhRMA Foundation, St. Jude Children’s Research Hospital, and Pfizer outside the submitted work. J.N.A. received research grants from the NIH and Gilead outside the submitted work. R.A.K. and Waters received research support from the NIH outside the submitted work. G.V. reported receiving personal fees from Roche/Genentech, Eli Lilly, Pfizer, and AstraZeneca, and research funding from Roche/Genentech, Puma, Celcuity, Merck, BMS, Eli Lilly, AstraZeneca, Gilead, GSK, Natera, Pfizer, Eisai, and ownership of Veris Health, all outside the submitted work. L.S.S. reported receiving personal fees from Pfizer, Helsinn, AstraZeneca, Genentech, Myriad, Napo, Eli Lilly, Coherus Biosciences, Foundation Medicine, Novartis, Daiichi Sankyo, Merck, GlaxoSmithKline, Sanofi, Mirati Therapeutics, and research support from Amgen and Pfizer outside the submitted work. No other disclosures were reported.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
The online version contains supplementary material available at 10.1038/s41523-026-00900-9.
References
- 1.Dumas, E. et al. Explaining the relationships between age, endocrine therapy persistence, and risk of recurrence in hormone receptor–positive early breast cancer: a nationwide cohort study. J. Clin. Oncol.43, 1863–1874 (2025). [DOI] [PubMed] [Google Scholar]
- 2.Hershman, D. L. et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J. Clin. Oncol.28, 4120–4128 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Narod, S. A. Breast cancer in young women. Nat. Rev. Clin. Oncol.9, 460–470 (2012). [DOI] [PubMed] [Google Scholar]
- 4.Balazard, F. et al. Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation. J. Natl. Cancer Inst.115, 1099–1108 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kadakia, K. C. & Henry, N. L. Adjuvant endocrine therapy in premenopausal women with breast cancer. Clin. Adv. Hematol. Oncol.13, 663–672 (2015). [PMC free article] [PubMed] [Google Scholar]
- 6.Francis, P. A. et al. Adjuvant ovarian suppression in premenopausal breast cancer. N. Engl. J. Med.372, 436–446 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Spencer, J. C., Reeve, B. B., Troester, M. A. & Wheeler, S. B. Factors associated with endocrine therapy non-adherence in breast cancer survivors. Psychooncology29, 647–654 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Cluze, C. et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann. Oncol.23, 882–890 (2012). [DOI] [PubMed] [Google Scholar]
- 9.Yussof, I., Mohd Tahir, N. A., Hatah, E. & Mohamed Shah, N. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review. Breast62, 22–35 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Estrela, M., Semedo, G., Roque, F., Ferreira, P. L. & Herdeiro, M. T. Sociodemographic determinants of digital health literacy: a systematic review and meta-analysis. Int. J. Med. Inform.177, 105124 (2023). [DOI] [PubMed] [Google Scholar]
- 11.Appiah, D., Nwabuo, C. C., Ebong, I. A., Wellons, M. F. & Winters, S. J. Trends in age at natural menopause and reproductive life span among US women, 1959-2018. JAMA325, 1328–1330 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Hu, X. et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor–positive breast cancer. JAMA Netw. Open5, e2225485–e2225485 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Yardley, L. et al. Understanding and promoting effective engagement with digital behavior change interventions. Am. J. Prev. Med.51, 833–842 (2016). [DOI] [PubMed] [Google Scholar]
- 14.Krukowski, R. A. et al. Symptom monitoring app use associated with medication adherence among woman survivors of breast cancer on adjuvant endocrine therapy. JCO Clin. Cancer Inform. e2400179. 10.1200/cci-24-00179 (2024). [DOI] [PMC free article] [PubMed]
- 15.Mubarak, F. & Suomi, R. Elderly forgotten? Digital exclusion in the information age and the rising grey digital divide. Inquiry59, 00469580221096272 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Paladino, A. J. et al. THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer. BMC Health Serv. Res.19, 977 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Graetz, I. et al. Remote monitoring app for endocrine therapy adherence among patients with early-stage breast cancer: a randomized clinical trial. JAMA Netw. Open7, e2417873–e2417873 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform.95, 103208 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.van Buuren, S., Boshuizen, H. C. & Knook, D. L. Multiple imputation of missing blood pressure covariates in survival analysis. Stat. Med.18, 681–694 (1999). [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
CONSORT_2025_editable_checklist THRIVE post hoc meno
Data Availability Statement
De-identified data used in this study are available from the corresponding author upon reasonable request.
The code used for these analyses is available from the corresponding author upon reasonable request.

